Secretory phospholipase A2 activity is linked to hypercholesterolemia and gender in non-alcoholic fatty liver disease individuals

Przeglad Gastroenterologiczny

Volumn 8, Issue 3, 2013, Pages 172-175

  Raszeja Wyszomirska, Joanna ^a   Safranow, Krzysztof ^a   Szynkowska, Agnieszka ^a   Stachowska, Ewa ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

8 epi PGF 2 III; Hydroxyoctadecadienoic acid; Isoprostane; Secretory phospholipase A2

Indexed keywords

13 HYDROXYOCTADECADIENOIC ACID; 8 ISOPROSTANE; 9 HYDROXYOCTADECADIENOIC ACID; ARACHIDONIC ACID DERIVATIVE; CHOLESTEROL; ISOPROSTANE 8 EPI PROSTAGLANDIN F2 ALPHA; LINOLEIC ACID; LIPID; PROSTAGLANDIN F2 ALPHA; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

EID: 84880354225     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2013.36330     Document Type: Article

References (11)

1. Federico A, D'Aiuto E, Borriello F, et al. Fat: a matter of distru-bance for the immune system. World J of Gastroenterol 2010; 16: 4762-72.
2. Feldstein AE, Lopez R, Tamimi TA, et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010; 5: 3046-54.
3. Hurt-Camejo E, Camejo G. Potential involvement of type II phospholipase A2 in atherosclerosis. Atherosclerosis 1997; 132: 1-8.
4. Hurt-Camejo E, Camejo G, Peilot H, et al. Phospholipase A(2) in vascular disease. Circ Res 2001; 89: 298-304.
5. Han WK, Sapirstein A, Hung CC, et al. Cross-talk between cyto-solic phospholipase A2 alpha (cPLA2 alpha) and secretory pho-spholipase A2 (sPLA2) in hydrogen peroxide-induced arachido-nic acid release in murine mesangial cells: sPLA2 regulates cPLA2 alpha activity that is responsible for arachidonic acid release. J Biol Chem 2003; 278: 24153-63.
6. Hurt-Camejo E, Camejo G, Sartipy P. Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 2000; 11: 465-71.
7. Colak Y, Senates E, Ozturk O, et al. Association of serum lipo-protein-associated phospholipase A2 level with nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2012; 10: 103-9.
8. Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Ste-atohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
9. Stachowska E, Dziedziejko V, Safranow K, et al. Effect of conjugated linoleic acids on the activity and mRNA expression of 5-and 15-lipoxygenases in human macrophages. J Agric Food Chem 2007; 55: 5335-2.
10. Raszeja-Wyszomirska J, Kurzawski G, Lawniczak M, et al. Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study. World J Gastroenterol 2010; 16: 2531-6.
11. Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54: 153-9.